EMA Takes Steps To Improve Predictability Of Drug Submissions
Executive Summary
The European Medicines Agency says it will become more systematic in seeking explanations from companies who delay or withdraw their planned marketing submissions and in chasing “no-shows.”
You may also be interested in...
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
Swissmedic Asks Sponsors For At Least Four Months’ Notice Ahead Of New Drug Filings
Companies looking to file medicines containing new active substances in Switzerland should notify the regulator up to six months before their planned submission date to support early planning activities, Swissmedic says.
EMA To Get Tough On Companies That Repeatedly Delay New Marketing Applications
Disappointed that its earlier initiative to improve the predictability of planned marketing authorization applications has failed to have an impact, the European Medicines Agency is discussing introducing more active measures as passive ones are not working.